Press Releases

THERAVET: SUCCESSFUL IPO ON EURONEXT GROWTH® PARIS AND BRUSSELS

 

June 11, 2021

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, is today announcing the results of its successful initial public offering on Euronext Growth® Paris and Brussels. ...

 

To view TheraVet's opening bell ceremony, click here.

Read more

 

 

 

PREVIOUS PRESS RELEASES

 

 

 

TheraVet: Initial Public Offering on Euronext Growth® Brussels and Paris

BIOCERA-VET: a promising alternative to autologous bone graft in canine arthrodesis

TheraVet announces the commercial launch of BIOCERA-VET

May 26, 2021

 

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, is today announcing an initial public offering with a view to having its shares admitted to trading on Euronext Growth® Brussels and Paris. ....

 

 

 

 

 

 

 

 

Read more

April  27, 2021

 

 

TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announces today the positive efficacy results of BIOCERA-VET, its new generation bone substitute for the treatment of bone surgeries in small companions, in bone fusion in canine arthrodesis. A real need for new bone substitute alternatives to replace effectively autologous bone graft in orthopedic surgeries For orthopedic surgeries, autologous bone graft is still considered as the standard of procedure to fill in cavities or to treat major defects with bone fusion such as arthrodesis. However, ...

 

 

Read more

April 01, 2021

 

 

TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, announced today the commercial launch of BIOCERA-VET, its new generation bone substitute for the treatment of bone surgeries in small companions. BIOCERA-VET will initially be commercialized on the Belgian orthopedic market and will quickly be extended to France and the Netherlands. Due to the growing importance of pets and of their quality of life for their owners, animal health is becoming more and more a social and medical issue ...

 

 

Read more

Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis


Positive results in canine cranial cruciate ligament deficiency


TheraVet raises 4 M€  to accelerate the development of its two veterinary products


March 04, 2021

 

Read more

January 26, 2021

 

Read more

December 10, 2020

 

Read more

TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma
TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis

November 17, 2020

 

Read more

June 15, 2020

 

Read more

This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies